Payment overview · 2025
General Payments
$903.92
43 reported records · 17 companies
Healthcare provider profile · identity verified
Ramesh Babu Konduru
Allopathic & Osteopathic Physicians|Internal Medicine · RALEIGH, NC · NPI 1477717445
Verified facts
What the public records show
CMS Open Payments records show Ramesh Babu Konduru received $903.92 in general payments during 2025 across 43 reported records.
Novo Nordisk Inc accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 873 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Austedo by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $302.88 | 33.5% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.21 | 10.1% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $71.62 | 7.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.92 | 6.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.36 | 5.2% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $43.49 | 4.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.80 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.10 | 3.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.52 | 3.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.30 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.07 | 3.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.84 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.00 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.13 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.87 | 2.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $18.17 | 2.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $903.92 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $214.79 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $102.92 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.21 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $71.62 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.36 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $39.80 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.76 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.10 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
873 | 94 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1408 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 1135 | 248 |
| Eliquis | Apixaban | 873 | 94 |
| Furosemide | Furosemide | 848 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 789 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 702 | 154 |
| Sertraline Hcl | Sertraline Hcl | 680 | 108 |
| Gabapentin | Gabapentin | 624 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 566 | 132 |
| Trazodone Hcl | Trazodone Hcl | 536 | 99 |
| Omeprazole | Omeprazole | 474 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 411 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 409 | 84 |
| Metformin Hcl | Metformin Hcl | 408 | 91 |
| Losartan Potassium | Losartan Potassium | 389 | 101 |
| Lisinopril | Lisinopril | 387 | 97 |
| Potassium Chloride | Potassium Chloride | 377 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 327 | 78 |
| Carvedilol | Carvedilol | 310 | 66 |
| Donepezil Hcl | Donepezil Hcl | 308 | 53 |
| Lactulose | Lactulose | 287 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 286 | 47 |
| Lorazepam | Lorazepam | 271 | 78 |
| Prednisone | Prednisone | 271 | 138 |
| Clopidogrel | Clopidogrel Bisulfate | 260 | 55 |
| Divalproex Sodium | Divalproex Sodium | 259 | 39 |
| Simvastatin | Simvastatin | 259 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 39 |
| Levetiracetam | Levetiracetam | 255 | 39 |
| Baclofen | Baclofen | 231 | 41 |
| Famotidine | Famotidine | 222 | 46 |
| Ibuprofen | Ibuprofen | 216 | 92 |
| Januvia | Sitagliptin Phosphate | 212 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 62 |
| Risperidone | Risperidone | 202 | 21 |
| Spironolactone | Spironolactone | 196 | 33 |
| Glimepiride | Glimepiride | 193 | 54 |
| Mirtazapine | Mirtazapine | 189 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 31 |
| Humalog Kwikpen U-100 | Insulin Lispro | 187 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 83 |
| Buspirone Hcl | Buspirone Hcl | 180 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 39 |
| Jardiance | Empagliflozin | 163 | 25 |
| Farxiga | Dapagliflozin Propanediol | 154 | 13 |
| Allopurinol | Allopurinol | 146 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 146 | 108 |
| Doxycycline Hyclate | Doxycycline Hyclate | 139 | 93 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 137 | 53 |
| Montelukast Sodium | Montelukast Sodium | 136 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 58 |
| Ezetimibe | Ezetimibe | 124 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 19 |
| Azithromycin | Azithromycin | 120 | 98 |
| Cefdinir | Cefdinir | 120 | 90 |
| Latanoprost | Latanoprost | 119 | 24 |
| Myrbetriq | Mirabegron | 118 | 12 |
| Alprazolam | Alprazolam | 117 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 19 |
| Tradjenta | Linagliptin | 111 | suppressed |
| Memantine Hcl | Memantine Hcl | 110 | 25 |
| Olanzapine | Olanzapine | 110 | 20 |
| Tramadol Hcl | Tramadol Hcl | 110 | 47 |
| Clozapine | Clozapine | 109 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 107 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 107 | 34 |
| Cephalexin | Cephalexin | 106 | 76 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 21 |
| Linzess | Linaclotide | 101 | 16 |
| Xarelto | Rivaroxaban | 101 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 65 |
| Metformin Hcl Er | Metformin Hcl | 96 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 18 |
| Levofloxacin | Levofloxacin | 95 | 77 |
| Clobetasol Propionate | Clobetasol Propionate | 91 | 49 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 29 |
| Bumetanide | Bumetanide | 83 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 82 | suppressed |
| Finasteride | Finasteride | 79 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 79 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 24 |
| Fluconazole | Fluconazole | 76 | 43 |
| Propranolol Hcl | Propranolol Hcl | 73 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 19 |
| Aripiprazole | Aripiprazole | 67 | 15 |
| Atenolol | Atenolol | 67 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 66 | 22 |
| Pregabalin | Pregabalin | 66 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Sucralfate | Sucralfate | 60 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 35 |
| Lamotrigine | Lamotrigine | 59 | 11 |
| Bupropion Xl | Bupropion Hcl | 58 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | suppressed |
| Novolog Flexpen | Insulin Aspart | 57 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 23 |
| Clonazepam | Clonazepam | 56 | 12 |
| Meloxicam | Meloxicam | 56 | 18 |
| Midodrine Hcl | Midodrine Hcl | 55 | suppressed |
| Topiramate | Topiramate | 55 | 11 |
| Methimazole | Methimazole | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 13 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 27 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 11 |
| Ozempic | Semaglutide | 48 | 15 |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 25 |
| Scopolamine | Scopolamine | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 20 |
| Nystatin | Nystatin | 43 | 26 |
| Terbinafine Hcl | Terbinafine Hcl | 43 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Metronidazole | Metronidazole | 42 | 33 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 39 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 39 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Lubiprostone | Lubiprostone | 38 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 37 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Nyamyc | Nystatin | 36 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Azelastine Hcl | Azelastine Hcl | 34 | 12 |
| Brilinta | Ticagrelor | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Nystop | Nystatin | 33 | 22 |
| Restasis | Cyclosporine | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Budesonide | Budesonide | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Austedo | Deutetrabenazine | 29 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 11 |
| Ramipril | Ramipril | 27 | suppressed |
| Tivicay | Dolutegravir Sodium | 27 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydroxyurea | Hydroxyurea | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 15 |
| Dimethyl Fumarate | Dimethyl Fumarate | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Buprenorphine | Buprenorphine | 19 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cyclosporine | Cyclosporine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 16 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | 17 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 12 |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Colchicine | Colchicine | 14 | 12 |
| Descovy | Emtricitabine/Tenofov Alafenam | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 11 |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 12 | 11 |
| Velphoro | Sucroferric Oxyhydroxide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $903.92 · 43 records | Novo Nordisk Inc | AFREZZA, AUSTEDO XR, CAPLYTA, DOVATO, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, INGREZZA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error